Alterity Therapeutics
ATHE
11 hedge funds and large institutions have $415K invested in Alterity Therapeutics in 2018 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 3 closing their positions.
0% more ownership
Funds ownership: 0.01% → 0.01% (+0%)
8% less funds holding
Funds holding: 12 → 11 (-1)
33% less capital invested
Capital invested by funds: $619K → $415K (-$204K)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$69.7K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$22.1K |
| 3 |
Morgan Stanley
New York
|
+$15.8K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$4.14K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$51K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$49K |
| 3 |
OIA
Optimum Investment Advisors
Chicago,
Illinois
|
-$3K |
ATHE Hedge Fund Activity: Q4 2018 in Review
11 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Alterity Therapeutics (ATHE) for Q4 2018, worth a combined $415K — down 33% from $619K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ATHE and 2 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 3 added.
The largest buyer was Susquehanna International Group, adding an estimated $69.7K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $51K sold.
- 11 institutional investors held Alterity Therapeutics (ATHE) as of Q4 2018, down from 12 in Q3 2018.
- Funds reported $415K of Alterity Therapeutics stock for Q4 2018, down 33% quarter-over-quarter.
- 2 funds opened new Alterity Therapeutics positions in Q4 2018 and 3 closed out, a net change of -1 holder.
- The largest Alterity Therapeutics buyer in Q4 2018 was Susquehanna International Group, an estimated $69.7K added.
- The largest Alterity Therapeutics seller in Q4 2018 was Renaissance Technologies, an estimated $51K sold.
Based on aggregated 13F filings for Q4 2018.